It is a GLP-1 receptor agonist with structural modifications, including a fatty-acid side chain, that extend its half-life enough to support once-weekly dosing
It exists for a critical reason
However, after that, she confirmed with the insurance company that coverage for Wegovy would mainly apply to certain conditions, but not for weight loss or obesity only
If the plan simply excludes weight-loss medication as a benefit, appealing rarely changes that, and the months spent fighting are months without treatment
However, research has shown that upwards of 95% of people suffering from obesity fail at their diet and exercise program
Sources Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence PMC TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial New England Journal of Medicine Lillys phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight Eli Lilly and Company NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current
